Relationships Between Low-Density Lipoprotein Particle Size, Plasma Lipoproteins, and Progression of Coronary Artery Disease: The Diabetes Atherosclerosis Intervention Study (DAIS)

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Circulation

• Publication date

  2003-04-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.0000057982.50167.6EPMID 12665498
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors in Lipid Metabolism and Atherosclerosis

  2002cited by this paper
• Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes.

  2002cited by this paper
• Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.

  2002cited by this paper
• Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events*

  2002cited by this paper
• LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins.

  2002cited by this paper
• Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study.

  2001cited by this paper
• Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.

  2001cited by this paper
• Comparison of Various Electrophoretic Characteristics of LDL Particles and Their Relationship to the Risk of Ischemic Heart Disease

  2001cited by this paper
• Low-density lipoprotein size, pravastatin treatment, and coronary events.

  2001cited by this paper
• Mortality and causes of death in the WHO multinational study of vascular disease in diabetes

  2001cited by this paper
• A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men.

  2001cited by this paper
• Laboratory standardization of a large international clinical trial: the DAIS experience. DAIS Project Group. Diabetes Atherosclerosis Intervention Study.

  2000cited by this paper
• Lipid intervention trials in diabetes.

  2000cited by this paper
• Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.

  1999cited by this paper
• Atherogenic lipoprotein phenotype in Type 2 diabetes: reversal with micronised fenofibrate

  1999cited by this paper
• Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

  1999cited by this paper
• Diabetes Atherosclerosis Intervention Study (DAIS): quantitative coronary angiographic analysis of coronary artery atherosclerosis.

  1998cited by this paper
• Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).

  1998cited by this paper
• The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS).

  1997cited by this paper
• Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans.

  1996cited by this paper
• The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization

  1996cited by this paper
• A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction.

  1996cited by this paper
• Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system.

  1996cited by this paper
• Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women.

  1996cited by this paper
• Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation.

  1995cited by this paper
• Apoprotein B structure and receptor recognition of triglyceride-rich low density lipoprotein (LDL) is modified in small LDL but not in triglyceride-rich LDL of normal size.

  1994cited by this paper
• Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B.

  1993cited by this paper
• Quantitative coronary angiography to measure progression and regression of coronary atherosclerosis. Value, limitations, and implications for clinical trials.

  1991cited by this paper
• Low-density lipoprotein subclass patterns and risk of myocardial infarction.

  1988cited by this paper
• Compensatory enlargement of human atherosclerotic coronary arteries.

  1987cited by this paper
• Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

  1972cited by this paper

• Low-density lipoprotein cholesterol to apolipoprotein B ratio as a predictor of clinical outcomes following percutaneous coronary intervention: a propensity score-matched analysis

  2025cites this paper
• Concordance & discordance analysis between LDLc and apolipoprotein B/Non HDLc among statin treated patients

  2024cites this paper
• Diabetes Mellitus and Cardiovascular Disease: Exploring Epidemiology, Pathophysiology, and Treatment Strategies

  2024cites this paper
• Atherogenic lipoproteins particle size and number are more critical determinant of cardiovascular risk than mass of cholesterol present within these – An overview

  2024cites this paper
• Current and Emerging Therapies for Atherosclerotic Cardiovascular Disease Risk Reduction in Hypertriglyceridemia

  2023cites this paper
• Benefits and harms of fibrate therapy in patients with type 2 diabetes: a systematic review and meta-analysis

  2023cites this paper
• A nano-enabledbiotinylated anti-LDL theranostic system to modulate systemic LDL cholesterol.

  2022cites this paper
• Interaction effect between fasting plasma glucose and lipid profiles on mortality of peritoneal dialysis patients

  2022cites this paper
• Identification of different lipoprotein response types in people following a Mediterranean diet pattern with and without whole eggs.

  2022cites this paper
• Sugar-Sweetened Beverage Consumption and Plasma Lipoprotein Cholesterol, Apolipoprotein, and Lipoprotein Particle Size Concentrations in US Adults

  2022cites this paper
• The relationship between triglyceride/high-density lipoprotein cholesterol ratio and coronary slow-flow phenomenon

  2021cites this paper
• Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes.

  2021cites this paper
• The relationship between triglyceride/high-density lipoprotein cholesterol ratio and coronary slow- ow phenomenon

  2021cites this paper
• Metabolism of Triglyceride-Rich Lipoproteins.

  2021cites this paper
• Combined lipid-lowering therapy from standpoint of modern guidelines for management of dyslipidaemias

  2021cites this paper
• Features of postoperative therapy in patients with type ІІ diabetes

  2020cites this paper
• Correlations between Iron Metabolism Parameters, Inflammatory Markers and Lipid Profile Indicators in Patients with Type 1 and Type 2 Diabetes Mellitus

  2020cites this paper
• Reduced oxidized LDL in T2D plaques is associated with a greater statin usage but not with future cardiovascular events

  2020cites this paper
• Nová hypolipidemika v léčbě diabetické dyslipidemie New hypolipidemic agents in the treatment of diabetic dyslipidemia

  2020cites this paper
• Genetic Mutations that Cause Coronary Artery Disease

  2020cites this paper
• A Four Month Randomized Controlled Trial on the Efficacy of Once-daily Fenofibrate Monotherapy in Persons with Spinal Cord Injury

  2019cites this paper
• Management of Low Density Lipoprotein Cholesterol at a primary care diabetes clinic in Kuwait.

  2019cites this paper
• Hypertriglyceridemic Waist: A Simple Marker of High‐Risk Atherosclerosis Features Associated With Excess Visceral Adiposity/Ectopic Fat

  2018cites this paper
• Stable coronary artery disease and endothelial progenitor cells.

  2018cites this paper
• Interleukin 2 receptor alfa gene polymorphism in type 1 Egyptian diabetics.

  2018cites this paper
• Genetic Markers for Coronary Artery Disease

  2018cites this paper
• Chromium supplementation for adjuvant treatment of type 2 diabetes mellitus: Results from a pooled analysis

  2018cites this paper
• New treatment options for lipid-lowering therapy in subjects with type 2 diabetes

  2018cites this paper
• Therapie der diabetischen Dyslipidämie

  2018cites this paper
• Metformin attenuates effects of cyclophilin A on macrophages, reduces lipid uptake and secretion of cytokines by repressing decreased AMPK activity.

  2018cites this paper
• Dyslipidemia in Type 2 Diabetic Patients

  2018cites this paper
• Reducing Cardiovascular Disease Risk in Youth with Type 2 Diabetes Through Dietary Carbohydrate Restriction: Clinical and Molecular Perspectives

  2017cites this paper
• Safety and efficacy of metformin up-titration in Japanese patients with type 2 diabetes mellitus treated with vildagliptin and low-dose metformin

  2017cites this paper
• Brief Review - Emerging Cardiac Biomarkers as Screening Tool for Atherosclerosis

  2017cites this paper
• Self-micellizing solid dispersions enhance the properties and therapeutic potential of fenofibrate: Advantages, profiles and mechanisms.

  2017cites this paper
• Atherogenic Dyslipidemia in Latin America : Prevalence , causes and treatment

  2017cites this paper
• Using the VAP lipid panel for the detection, evaluation, and treatment of patients “at risk” for CAD

  2017cites this paper
• Atherogenic dyslipidemia in Latin America: prevalence, causes and treatment. Consensus

  2017cites this paper
• The Microvascular and Macrovascular Benefits of Fibrates in Diabetes and the Metabolic Syndrome: A review.

  2017cites this paper
• DISLIPIDEMIA ATEROGÉNICA EN LATINO AMÉRICA: PREVALENCIA, CAUSAS Y TRATAMIENTO

  2017cites this paper
• medigraphic . org . mx Atherogenic dyslipidemia in Latin America : prevalence , causes and treatment

  2017cites this paper
• [Hypertriglyceridemia and ischemic heart disease: Is a risk factor ?].

  2016cites this paper
• Serum CETP status is independently associated with reduction rates in LDL-C in pitavastatin-treated diabetic patients and possible involvement of LXR in its association

  2016cites this paper
• Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial.

  2016cites this paper
• All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT

  2016cites this paper
• A study of dyslipidaemia among patients with type 2 diabetes in the Northern Province of Sri Lanka

  2016cites this paper
• A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever

  2016cites this paper
• Statins and fibrates as the treatment of nonproliferative diabetic retinopathy in type 2 diabetes mellitus

  2016cites this paper
• Dilucidando el mecanismo de acción de los fibratos

  2016cites this paper
• New insights into the pathophysiology of dyslipidemia in type 2 diabetes.

  2015cites this paper
• Development of omega-3 phospholipid-based solid dispersion of fenofibrate for the enhancement of oral bioavailability.

  2015cites this paper
• Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus--systematic review and meta-analysis.

  2015cites this paper
• Drugs in the Primary and Secondary Prevention of Coronary Artery Disease

  2015cites this paper
• Genetics of Non-conventional Lipoprotein Fractions

  2015cites this paper
• Pathophysiology of diabetic dyslipidaemia: where are we?

  2015cites this paper
• Changes in lipid and carbohydrate metabolism under mTOR- and calcineurin-based immunosuppressive regimen in adult patients after liver transplantation.

  2015cites this paper
• A novel truncated form of apolipoprotein A-I transported by dense LDL is increased in diabetic patients1[S]

  2015cites this paper
• Comparison of the efficacy of fenofibrate and acipimox on plasma lipoprotein subclasses distribution in the Chinese population with Type 2 diabetes mellitus and hypertriglyceridemia

  2014cites this paper
• Correlation between serum levels of small, dense low-density lipoprotein cholesterol and carotid stenosis in cerebral infarction patients >65 years of age.

  2014cites this paper
• Human LDL Structural Diversity Studied by IR Spectroscopy

  2014cites this paper
• Confronting the residual cardiovascular risk beyond statins: the role of fibrates, omega-3 fatty acids, or niacin, in diabetic patients.

  2014cites this paper
• Genetic Risk Scores Associated with Baseline Lipoprotein Subfraction Concentrations Do Not Associate with Their Responses to Fenofibrate

  2014cites this paper
• Melatonin’s Beneficial Effects in Metabolic Syndrome with Therapeutic Applications

  2014cites this paper
• Fibrate Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients

  2014cites this paper
• Evidence That Multiple Defects in Lipid Regulation Occur before Hyperglycemia during the Prodrome of Type-2 Diabetes

  2014cites this paper
• Apolipoprotein B in Patients with Cardiovascular Risk

  2013cites this paper
• STUDIES ON THE REGULATION OF FGF21 GENE EXPRESSION BY (R)-α-LIPOIC ACID: MECHANISTIC INSIGHT INTO THE LIPID LOWERING PROPERTIES OF A DITHIOL DIETARY MOLECULE

  2013cites this paper
• Hypertriglyceridemia

  2013cites this paper
• Dynamic changes of lipid profile in Romanian patients with Gaucher disease type 1 under enzyme replacement therapy: a prospective study

  2013cites this paper
• An overview on management of diabetic dyslipidemia

  2013cites this paper
• Short-term estimation and application of biological variation of small dense low-density lipoproteins in healthy individuals

  2013cites this paper
• The role of fibrate treatment in dyslipidemia: an overview.

  2013cites this paper
• Effects of patient‐tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low‐density lipoprotein cholesterol in patients with type 2 diabetes

  2013cites this paper
• Changes in Small Dense Low-Density Lipoprotein Levels Following Acute Coronary Syndrome

  2013cites this paper
• Background Diet and Fat Type Alters Plasma Lipoprotein Response but not Aortic Cholesterol Accumulation in F1B Golden Syrian Hamsters

  2013cites this paper
• Reversal of obesity-induced hypertriglyceridemia by (R)-α-lipoic acid in ZDF (fa/fa) rats.

  2013cites this paper
• Small dense low-density lipoproteins cholesterol can predict incident cardiovascular disease in an urban Japanese cohort: the Suita study.

  2013cites this paper
• Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial

  2013cites this paper
• Towards Independent Particle Reconstruction from Cryogenic Transmission Electron Microscopy

  2013cites this paper
• Clinical utility of low-density lipoprotein particles and apolipoprotein B in patients with cardiovascular risk.

  2013cites this paper
• The Mean Platelet Volume and Atherogenic Index of Plasma in Nondipper Normotensive Individuals Compared to Dippers

  2013cites this paper
• Evaluation of association between atherogenic index of plasma and intima‐media thickness of the carotid artery for subclinic atherosclerosis in patients on maintenance hemodialysis

  2013cites this paper
• Association of the PGC-1α rs8192678 Variant with Microalbuminuria in Subjects with Type 2 Diabetes Mellitus

  2012cites this paper
• Lipoproteins and Cardiovascular Diseases Adebowale Saba and Olayinka Oridupa

  2012cites this paper
• Role of Fibric Acid Derivatives in the Management of Risk Factors for Coronary Heart Disease

  2012cites this paper
• Mejoría del perfil de lípidos y la función endotelial con fenofibrato en pacientes con síndrome metabólico y nivel de C-LDL dentro del objetivo terapéutico

  2012cites this paper
• Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials.

  2012cites this paper
• Small dense low-density lipoprotein particles: priority as a treatment target in Type 2 diabetes?

  2012cites this paper
• Fibrates and cardiorenal outcomes.

  2012cites this paper
• Sex-specific differences in Type 2 Diabetes Mellitus and dyslipidemia therapy: PPAR agonists.

  2012cites this paper
• ‘Triglyceride effect’ on the dynamics of plasma lipoproteins and its possible link to atherogenesis

  2012cites this paper
• Lipoproteins and Cardiovascular Diseases

  2012cites this paper
• Mechanisms of diabetic dyslipidemia: relevance for atherogenesis.

  2012cites this paper
• Fenofibrate: Panacea for Aging-Related Conditions?

  2012cites this paper
• EFFECTS OF HYPOLIPIDEMIC AND HYPOGLYCAEMIC DRUGS ON ATHEROGENIC LOW-DENSITY LIPOPROTEINS PARTICLES IN TYPE-2 DIABETES

  2012cites this paper
• Impact of Treating Dyslipidemia on Cardiovascular Events

  2011cites this paper
• Effect of Bezafibrate on Monocyte Cytokine Release and Systemic Inflammation in Patients With Impaired Fasting Glucose

  2011cites this paper
• Treatments for the Metabolic Syndrome

  2011cites this paper
• Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes

  2011cites this paper
• Association of Cold Receptor TRPM8 Gene Polymorphism with Blood Lipid Indices and Anthropometric Parameters in Shorians

  2011cites this paper